A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
The Company Accuray Incorporated is a radiation therapy company that develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments for even the most complex cases, while making commonly treatable cases even more straightforward, to meet the full spectrum of patient needs. We believe in comparison to conventional linear accelerators, our treatment delivery, planning, and data management solutions provide better accuracy, flexibility, and control; fewer treatments with shorter treatment times; and the technology to expand beyond cancer, making it easier for clinical teams around the world to provide treatments that help patients get back to living their lives, faster. Our solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 437M | 459M | 447M | 448M | 430M | 396M |
| Net Income | -36M | -1.6M | -16M | -9.3M | -5.3M | -6.3M |
| EPS | $-0.31 | $-0.02 | $-0.16 | $-0.10 | $-0.06 | $-0.07 |
| Free Cash Flow | -2.7M | -1.4M | -16M | 2.9M | -7.1M | 36M |
| ROIC | -11.8% | 3.9% | -0.2% | 2.8% | 9.7% | 56.6% |
| Gross Margin | 27.8% | 32.1% | 32.0% | 34.4% | 37.2% | 40.3% |
| Debt/Equity | 2.75 | 2.33 | 4.85 | 3.93 | 3.91 | 2.95 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -18M | 7.8M | -196K | 2.4M | 8.1M | 22M |
| Operating Margin | -4.0% | 1.7% | -0.0% | 0.5% | 1.9% | 5.6% |
| ROE | -66.7% | -2.5% | -34.5% | -17.3% | -10.1% | -9.2% |
| Shares Outstanding | 119M | 80M | 97M | 93M | 89M | 90M |
ACCURAY INC passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 14.6% with a gross margin of 35.2%. At current prices, the estimated annualized return to fair value is -14.3%.
ACCURAY INC (ARAY) has a 5-year average return on invested capital (ROIC) of 14.6%. This indicates solid capital allocation.
ACCURAY INC (ARAY) has a market capitalization of $48M. It is classified as a small-cap stock.
ACCURAY INC (ARAY) does not currently pay a regular dividend.
ACCURAY INC (ARAY) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
ACCURAY INC (ARAY) reported annual revenue of $459 million in its most recent fiscal year, based on SEC EDGAR filings.
ACCURAY INC (ARAY) has a net profit margin of -0.3%. The company is currently unprofitable.
ACCURAY INC (ARAY) generated $-1 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ACCURAY INC (ARAY) has a debt-to-equity ratio of 2.33. This indicates higher leverage, which may increase financial risk.
ACCURAY INC (ARAY) reported earnings per share (EPS) of $-0.02 in its most recent fiscal year.
ACCURAY INC (ARAY) has a return on equity (ROE) of -2.5%. A negative ROE may indicate losses or negative equity.
ACCURAY INC (ARAY) has a 5-year average gross margin of 35.2%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for ACCURAY INC (ARAY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ACCURAY INC (ARAY) has a book value per share of $1.02, based on its most recent annual SEC filing.
No recent press releases.